Markets
TSX21149.00+23.10
TSXV954.26+10.21
DOW35135.94+236.60
S&P 5004655.27+60.65
NASD15782.83+291.18
ASX7239.80-39.50
Commodities
Gold1795.85+9.21
Silver22.89-0.04
Copper4.30-0.04
Palladium1785.18-3.73
Platinum950.38-15.62
Oil68.36-1.59
Heating Oil2.10-0.05
Natural Gas4.73-0.12
Currencies
BTCUSD56054.17-1802.76
USDCAD1.2797+0.0060
USDEUR0.8840-0.0015
USDGBP0.7511+0.0001
USDAUD1.4087+0.0096
USDJPY113.05-0.75

BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights

- Announced positive findings from the Phase 2b SOOTHE trial administrative interim analysis, with at least one dose of BLU-5937 meeting the threshold for a high probability of clinical efficacy -

- Phase 2b SOOTHE and Phase 2a BLUEPRINT trials are fully enrolled, with topline results expected in December 2021 -

Keep reading... Show less

BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937

- Live webcast to be held on November 15 th at 12:00 p.m. EST –

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that it will convene a virtual analyst event to discuss the chronic cough landscape and its selective P2X3 antagonist, BLU-5937, on Monday, November 15, 2021 at 12:00 p.m. EST.

Keep reading... Show less

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis

Topline results from both studies are expected in December 2021

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic pruritus associated with atopic dermatitis ("AD"). Topline results from both trials are expected in December 2021.

Keep reading... Show less